With a string of news coming from drug firm Lupin , the company further expects about 14 to 15 launches in the course of this year. Company’s CFO, S Ramesh tells CNBC-TV18 that the company has a pipeline of over 150 drugs that await approval for the American market from the US Food and Drug Administration (FDA).
Lupin had got a nod from the US health regulators yesterday to market generic levofloxacin tablets that are used for the treatment of bacterial infections, in the American market. “There is intense competition in the product. Though the revenues from this used to be priced at 1.3 billion; there has been tremendous price erosion in that drug,” said Ramesh. He said it is going to be a marginal product and believes there will be about six to sever players.
Lupin also partnered with Hyderabad-based Natco Pharma for a generic version of Lapatinib Ditosylate tablets of 250 mg strength, used for the treatment of breast cancer. “ Natco is the first to file for it and we are helping them to distribute in America . It would add to the bottom-line over a period of time,” he said. Ramesh also revealed the drug would be worth USD 130 million.
No comments:
Post a Comment